

## Freeform Search

---

**Database:** 
 US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

**Term:**

**Display:** 10 **Documents in Display Format:** DATE **Starting with Number** 1

**Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

---

Search
Clear
Interrupt

---

### Search History

---

**DATE:** Monday, August 02, 2004    [Printable Copy](#)    [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L31</u>	l1 and l30	1	<u>L31</u>
<u>L30</u>	L29 and l2	1	<u>L30</u>
<u>L29</u>	6248588.pn.	2	<u>L29</u>
<u>L28</u>	L27 and l1	2	<u>L28</u>
<u>L27</u>	L26 and l2	7	<u>L27</u>
<u>L26</u>	5100784	14	<u>L26</u>
<u>L25</u>	L24 and l1	0	<u>L25</u>
<u>L24</u>	l2 and l23	2	<u>L24</u>
<u>L23</u>	4914027.pn.	2	<u>L23</u>
<u>L22</u>	L21 and l2	0	<u>L22</u>
<u>L21</u>	3783098.pn.	4	<u>L21</u>
<u>L20</u>	l2 and l19	0	<u>L20</u>
<u>L19</u>	5126242.pn.	2	<u>L19</u>
<u>L18</u>	l2 and l17	0	<u>L18</u>
<u>L17</u>	400256.pn.	6	<u>L17</u>
<u>L16</u>	l2 and l14	0	<u>L16</u>

<u>L15</u>	l4 and l14	0	<u>L15</u>
<u>L14</u>	5700470.pn.	2	<u>L14</u>
<u>L13</u>	L12 same l3	6	<u>L13</u>
<u>L12</u>	concentration	1340886	<u>L12</u>
<u>L11</u>	l8 same l3	4	<u>L11</u>
<u>L10</u>	l9 same l3	3	<u>L10</u>
<u>L9</u>	stabi\$	1809676	<u>L9</u>
<u>L8</u>	titer	40578	<u>L8</u>
<u>L7</u>	L6 same l3	5	<u>L7</u>
<u>L6</u>	replication defective or replication	78475	<u>L6</u>
<u>L5</u>	L4 same l3	32	<u>L5</u>
<u>L4</u>	albumin	86852	<u>L4</u>
<u>L3</u>	L2 with l1	63	<u>L3</u>
<u>L2</u>	human serum albumin or hsa	14078	<u>L2</u>
<u>L1</u>	adenovir\$	32508	<u>L1</u>

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L5: Entry 9 of 32

File: USPT

Feb 24, 2004

DOCUMENT-IDENTIFIER: US 6696420 B1

TITLE: Adenoviral vector with a deletion in the E1A coding region expressing a heterologous protein

Detailed Description Text (41):

The recombinant adenovirus Ad5(M-B) therefore directs in vivo the synthesis of HBsAg particles having the character of a receptor for polymerized human serum albumin.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L5: Entry 11 of 32

File: USPT

Feb 3, 2004

DOCUMENT-IDENTIFIER: US 6686179 B2

**\*\* See image for Certificate of Correction \*\***

TITLE: Fusion polypeptides of human serum albumin and a therapeutically active polypeptide

Other Reference Publication (31):Ballay, A., et al., "In vitro and in vivo Synthesis of the Hepatitis B Virus Surface Antigen and of the Receptor for Polymerized Human Serum Albumin from Recombinant Human Adenoviruses," The Embo Journal 4:3861-3865 (1985).[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L5: Entry 31 of 32

File: DWPI

Jul 1, 2003

DERWENT-ACC-NO: 2000-206000

DERWENT-WEEK: 200366

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New composition useful for preservation of viral particles by enhancing vector titer and/or stabilizing vector at refrigerator or room temperature, comprising recombinant adenovirus vector and human serum albumin

Basic Abstract Text (1):

NOVELTY - A composition (I), comprising a recombinant adenovirus vector (II) and a concentration of human serum albumin (HSA), is new and stabilizes (II) at a temperature above the freezing point of water or enhances a titer of (II) compared to a titer in the absence of HSA, or both, in an aqueous buffer.

Standard Title Terms (1):

NEW COMPOSITION USEFUL PRESERVE VIRUS PARTICLE ENHANCE VECTOR STABILISED VECTOR REFRIGERATE ROOM TEMPERATURE COMPRISE RECOMBINATION ADENOVIRUS VECTOR HUMAN SERUM ALBUMIN

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 19:10:59 ON 02 AUG 2004

=> file medline cancerlit biotechds embase biosis caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 19:11:17 ON 02 AUG 2004

FILE 'CANCERLIT' ENTERED AT 19:11:17 ON 02 AUG 2004

FILE 'BIOTECHDS' ENTERED AT 19:11:17 ON 02 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'EMBASE' ENTERED AT 19:11:17 ON 02 AUG 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 19:11:17 ON 02 AUG 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CAPLUS' ENTERED AT 19:11:17 ON 02 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s human serum albumin and adenovir?  
L1 43 HUMAN SERUM ALBUMIN AND ADENOVIR?

=> dup rem l1  
PROCESSING COMPLETED FOR L1  
L2 22 DUP REM L1 (21 DUPLICATES REMOVED)

=> d bib ab 1-22

Last Updated on STN: 29 Aug 1987

L2 ANSWER 19 OF 22 MEDLINE on STN DUPLICATE 7  
AN 86136028 MEDLINE  
DN PubMed ID: 3004975  
TI In vitro and in vivo synthesis of the hepatitis B virus surface antigen  
and of the receptor for polymerized **human serum**  
**albumin** from recombinant human **adenoviruses**.  
AU Ballay A; Levrero M; Buendia M A; Tiollais P; Perricaudet M  
SO EMBO journal, (1985 Dec 30) 4 (13B) 3861-5.  
Journal code: 8208664. ISSN: 0261-4189.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198604  
ED Entered STN: 19900321  
Last Updated on STN: 19900321  
Entered Medline: 19860411  
AB We have developed an **adenovirus** vector to express foreign  
proteins under the control of the **adenovirus** Ela promoter. Two  
recombinant plasmids, harbouring either the S gene or the pre-S2 region  
and the S gene of hepatitis B virus under the control of the Ela promoter,  
were used to construct two recombinant **adenoviruses**. These two  
viruses direct the synthesis of hepatitis B virus surface antigen (HBsAg)  
particles during the time course of an infectious cycle. When the pre-S2  
region is present in the constructed virus, the synthesis of particles  
carrying the receptor for polymerized **human serum**  
**albumin** (pHSA) is observed. Moreover, the inoculation of rabbits  
with this latter purified recombinant **adenovirus** elicits the  
production of antibodies that react with both HBsAg and pHSA receptor.

L2 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2000:133817 CAPLUS  
 DN 132:162036  
 TI Preservation of **adenovirus** vector for gene therapy using  
 formulations comprising **human serum albumin**  
 IN Shih, Shian Kiun; McGlennon, Karen R.; Moody, Dewey  
 PA Aventis Pharmaceuticals Products Inc., USA  
 SO PCT Int. Appl., 53 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000009675	A1	20000224	WO 1999-US18515	19990813
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2340682	AA	20000224	CA 1999-2340682	19990813
	AU 9954858	A1	20000306	AU 1999-54858	19990813
	AU 748523	B2	20020606		
	EP 1109896	A1	20010627	EP 1999-941147	19990813
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003528029	T2	20030924	JP 2000-565112	19990813
PRAI	US 1998-96600P	P	19980814		
	WO 1999-US18515	W	19990813		

AB The present invention relates to a formulation allowing the preservation  
 of viral particles and viral vectors, which is directly injectable into an  
 organism. It relates more particularly to a formulation for the  
 preservation of a recombinant **adenovirus** vector that optimally  
 enhances the vector titer, or stabilizes the vector at refrigerator or  
 room temperature, or both. The invention relates to compns. comprising a  
 recombinant **adenovirus** vector and a concentration of **human**  
**serum albumin** (HSA) effective to stabilize the  
**adenovirus** vector at a temperature above the f.p. of water or to enhance  
 a titer of the **adenovirus** vector compared to a titer in the  
 absence of HSA, or both, in an aqueous buffer.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILA



L2 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:833498 CAPLUS  
 DN 135:355025  
 TI Use of serum albumin for inhibiting aggregation during filtration in virus  
 vector preparation  
 IN Takashima, Shigemitsu; Heike, Yuji  
 PA Welfide Corporation, Japan  
 SO PCT Int. Appl., 27 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085928	A1	20011115	WO 2001-JP3877	20010509
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001056675	A5	20011120	AU 2001-56675	20010509
	EP 1284287	A1	20030219	EP 2001-930008	20010509
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004101964	A1	20040527	US 2003-275708	20030128
PRAI	JP 2000-137302	A	20000510		
	WO 2001-JP3877	W	20010509		
AB	A method of preparing a virus vector by inhibiting aggregation involving the steps of (1) purifying a virus vector, and (2) sterilizing the purified vector obtained in the above (1) by filtering in the presence of serum albumin; and medicinal compns. containing a virus vector and serum albumin; are disclosed. Addition of serum albumin will result in inhibition of aggregation when carrying out filtration and thus stabilization. Use of ultracentrifuge, dialysis, and ion-exchange, is also claimed. <b>Adenovirus</b> , adeno-associated virus, retrovirus, herpes virus, or lentivirus vectors are used. Substantial reduction in aggregation upon filtration by the use of platelet derived and recombinant <b>human serum albumin</b> (HSA), bovine serum albumin (BSA), and FBS, in <b>adenovirus</b> vector preparation, was observed				